Imatinib
Imatinib Phase 3 dose trials (combined analysis on label)
Novartis · Phase 3 · Completed · Enrollment 1640
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Imatinib 400 mg daily | unresectable or metastatic KIT (CD117) positive GIST | 400 mg | ITT | n/r | median progression-free survival: 18.9 months, median follow up 37.5 monthsmedian overall survival: 49 months, median follow up 37.5 monthsbest overall response (complete 5.3% plus partial 46.1%): 51.4%, combined analysis, Sum of label complete response 43 (5.3%) and partial response 377 (46.1%) |
| Imatinib 800 mg daily | unresectable or metastatic KIT (CD117) positive GIST | 800 mg | ITT | imatinib 400 mg | median progression-free survival: 23.2 months, median follow up 37.5 monthsmedian overall survival: 48.7 months, median follow up 37.5 months |